A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model

por Kratzer, Roland, Sansas, Benoît, Lélu, Karine, Evlachev, Alexei, Schmitt, Doris, Silvestre, Nathalie, Inchauspé, Geneviève, Martin, Perrine
Publicado 2018

Intravenous injection of a novel viral immunotherapy encoding human interleukin-7 in nonhuman primates is safe and increases absolute lymphocyte count

por Coupet, Charles-Antoine, Dubois, Clarisse, Evlachev, Alexeï, Kehrer, Nadine, Baldazza, Marie, Hofman, Sam, Vierboom, Michel, Martin, Perrine, Inchauspe, Geneviève
Publicado 2022

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

por Martin, Perrine, Dubois, Clarisse, Jacquier, Emilie, Dion, Sarah, Mancini-Bourgine, Maryline, Godon, Ophélie, Kratzer, Roland, Lelu-Santolaria, Karine, Evlachev, Alexei, Meritet, Jean-François, Schlesinger, Yasmin, Villeval, Dominique, Strub, Jean-Marc, Van Dorsselaer, Alain, Marchand, Jean-Baptiste, Geist, Michel, Brandely, Renée, Findeli, Annie, Boukhebza, Houda, Menguy, Thierry, Silvestre, Nathalie, Michel, Marie-Louise, Inchauspé, Geneviève
Publicado 2015